Hope you're week's treating all of you well. While we continue to get more upside in equities, we got more good news this morning from a few of our featured stocks, and if what's starting to develop with a number of our smaller penny plays starts to pan out, we could be looking at some pretty big gains very soon. First, scientists are often not the best communicators, and definitely aren't the best sales people. At least not like the Mark Cubans of the world, who always seem to know how to say the right things at the right time, and equally as important know how to get the masses to understand and buy into a message. Yet, underneath all of their scientific madness - see Mad Magazine, a throwback to the ideal - there's often diamonds in the rough, despite their limited ability at times to communicate effectively. This isn't a dig of sorts, it's a very real reality, one that often plagues small and large public companies alike, especially in the biotech and medical space. However, when it's all said and done, it reminds me of one of my favorite mottos of all-time, "actions not words please". One of those instances involves a relatively unknown company, Algae Dynamics Corp. (ADYNF), a Canadian based R&D biotech company focused on algae and cannabis oil extracts, who filed an 8K just this morning, and issued a press release regarding the Company's business strategy, which has previously had a bit of a hard time effectively communicating their story. Well, not only did they lay it out plain old English, they did it in such a way that it's going to be pretty hard for everyone NOT to understand what they're doing and where they're planning on going. And, I must say, this is one Company I do think investors should step up and take notice of quickly. We all know Canada is well ahead of the U.S. in terms of legalizing cannabis for medical purposes, and there appears to be a very good chance it's going to get approved at some point over the next few years for recreational use as well. It's no guarantee, but it does appear the writing's on the wall. Furthermore, you can dig up all of the stats you want to on the topic, but the reality is cannabis, and everything associated with it, is already a very booming industry - one that eerily mirrors that of what took place during the post prohibition era when alcohol companies started making a mint. Although I'm no expert on the topic, I do no math very well, and if Algae Dynamics Corp. can deliver on even a half of what the Company revealed earlier today, speculative investors willing to take a shot on shares of ADYNF could end up making a fortune someday, regardless of whether or not the U.S. or Canada ever legalizes cannabis completely. Why? Because there's already enough revenue within the budding industry (no pun intended), to put market caps and valuations on certain stocks that well exceed many of their current levels. Have a look at AbbVie (ABBV), GW Pharmaceuticals (GWPH), Insys Therapeutics (INSY) and Cara Therapeutics (CARA), just to name a few. Look at some of the runs they've made over the last few years to even the last few months in some cases. You'll see the space is heating up like nothing we've seen since the dot com boom. However, like with any new revolutionary opportunity, you have pretenders and you have some very real legitimate players, and considering Algae Dynamics Corp. has been involved in oil extraction for quite some time, it's my thinking the Company's shift and focus over into the cannabinoid space is one that should suit the Company well. Not only is there a tremendous appetite for oil's ranging from algae to cannabis with today's modern day health conscious consumer, the health benefits associated with them are starting to garner more and more interest. And, Algae Dynamics has research and collaboration agreements with three extremely well respected entities: University of Western Ontario, University of Waterloo and ARA - Avanti Rx Analytics. The latter is a much bigger deal than many might think, as ARA - Avanti Rx Analytics already has approved licenses from Health Canada, something many simply do not. As for shares of ADYNF, you can clearly see it's not getting all that much attention, but I've been known for years to say the best time to buy a penny stock is when nobody else wants them, because at some point just about every last one of them does end up making some sort of substantial move higher. Although many do end up failing when it's all said and done, something tells me ADYNF is worth the risk. If not for a massive homerun someday, at least for some tremendous gains once cannabis traders find this one in the weeds. I strongly suggest you have a good read of the strategy Algae Dynamics Corp. clearly laid out for its investors this morning, it's full of detail and the direction is now crystal clear. Here's a link to the Company's PR in its entirety: https://www.otcmarkets.com/stock/ADYNF/news and here's a direct link to the presentation I'm referring to: http://www.algaedynamics.com/files/ADC-Company-PPT-March-28-2017.pdf. VentriPoint Diagnostics Ltd. (VPTDF) - Tackling Heart Disease Before It's Fatal Earlier this morning, VentriPoint Diagnostics Ltd. (VPTDF) (VPT.V) released news regarding a quick video clip that was recently made available at Business News Network (BNN), Canada's only all business specialty channel with real time coverage of global market activity from a Canadian perspective. The short clip provided a picture that was well... worth a thousand words as the clich'e goes. Basically, it was a 3D image of a heart. So many might say big deal, right? Well, quite honestly it is a big deal, because to our knowledge, there's no other quick and inexpensive way out there that we know of, whereby someone can walk into a clinic and quickly have a 3D image of their heart taken, until now. It really isn't the video that's so compelling, it's VentriPoint Diagnostics' new VMS machine that is revolutionizing the way cardiologists look at hearts by converting ultrasound slices into a 3D hologram. The Company has recently redesigned VMS to meet the demands of every market - preparing to move beyond the Left and Right Ventricle to become the first platform to offer 3D volumes for all cardiac chambers, with accuracy equivalent to MRI, all from the convenience of 2D Ultrasound. Anytime I look at a small or micro cap idea, I ask myself the following question - can the company in question change lives, change trends, or change the future of the industry they're in? In VentriPoint's case, I have to say that would be a resounding yes. At least for the first and third parts of that question, as the trend component is more of a consumer driven type scenario. Although the Company clearly has a ways to go on the revenue and earnings front, should VentriPoint's technology really start to take hold, which it's already being used in several hospitals around the world, the potential for VPTDF becomes quite compelling. Just consider some basic facts I pulled from cardiosmart.org just a few minutes ago. In 2008, over 616,000 people died of heart disease. In 2008, heart disease caused almost 25% of deaths-almost one in every four-in the United States. Heart disease is the leading cause of death for both men and women. More than half of the deaths due to heart disease in 2008 were in men. Coronary heart disease is the most common type of heart disease. In 2008, 405,309 people died from coronary heart disease. Every year about 785,000 Americans have a first coronary attack. Another 470,000 who have already had one or more coronary attacks have another attack. In 2010, coronary heart disease alone was projected to cost the United States $108.9 billion. This total includes the cost of health care services, medications, and lost productivity. Source: Centers for Disease Control and Prevention When one considers the magnitude of heart disease in this country, and how many of those cases could potentially be helped before they become fatal, it's no wonder the Company's dual listed stock in Canada, under the ticker symbol VPT.V, is getting so much attention. The weird part, however, is the Company still doesn't quite get the attention it deserves here in the U.S. Well, for those of you who will get to know me here at SCN, let me just say I call everything the way I see it, and there's no question when it comes to small penny stocks, Canada knows how to speculate far better than those American penny players. Give this one some time, and we might end up seeing VPTDF start getting the same type of attention. If you're interested in seeing the short video clip, just go here: http://www.b-tv.com/ventripoint-diagnostics-commercial/. However, far more compelling would be to go to an actual video demo at the Company's web site here: http://www.ventripoint.com/video-demo.html.